Previous 10 | Next 10 |
Gainers: OMNOVA Solutions (NYSE: OMN ) +55% . SELLAS Life Sciences Group (NASDAQ: SLS ) +46% . Karyopharm Therapeutics (NASDAQ: KPTI ) +36% . One Stop Systems (NASDAQ: OSS ) +26% . NIO (NYSE: NIO ) +15% . Corvus Pharmaceuticals (NASDAQ: CRVS ) +15% . Melinta Therapeutics (NASDA...
Noteworthy events during the week of June 30 - July 6 for healthcare investors. More news on: Jazz Pharmaceuticals plc, Celyad SA, Array BioPharma Inc., Healthcare stocks news, , Read more ...
-- Single-Agent Oral Selinexor Induces a 28.3% Overall Response Rate, Including a 10.2% Complete Response Rate -- -- Amongst Patients with a Complete or Partial Response, Median Duration of Response was 9.2 Months -- NEWTON, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Karyopharm...
Karyopharm Therapeutics (NASDAQ: KPTI ) gains 4.0% in premarket trading after presenting new and updated data from its Phase 1b/2 STOMP study evaluating selinexor and dexamethasone in combination with standard approved multiple myeloma therapies in patients with previously treate...
− Once Weekly Oral Selinexor in Combination with Kyprolis® and Low Dose Dexamethasone Demonstrates 78% ORR in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma – − Once Weekly Oral Selinexor in Combination with Darzalex® and Low Dose...
Noteworthy events during the week of June 9 - 15 for healthcare investors. More news on: Merck & Co., Inc., Xeris Pharmaceuticals, Inc., Mallinckrodt plc, Healthcare stocks news, , Read more ...
The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with this Read more ...
-- Oral Presentation Highlighting Updated Data from the Phase 1b/2 STOMP Study Arm Evaluating Selinexor and Dexamethasone in Combination with Darzalex® in Patients with Relapsed or Refractory Multiple Myeloma -- -- Two Posters Highlighting Updated Data from the STOMP Arms Evaluat...
Karyopharm Therapeutics Inc. (KPTI) Q1 2019 Results Conference Call May 09, 2019 08:30 AM ET Company Participants Ian Karp - VP, IR and Public Relations Dr. Michael Kauffman - CEO Mike Mason - CFO Anand Varadan - Chief Commercial Officer Conference Call Participants Brian...
Karyopharm Therapeutics (NASDAQ: KPTI ): Q1 GAAP EPS of -$1.09 misses by $0.23 . More news on: Karyopharm Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress PR Newswire – Achieves Second Quarter 2024 Total Revenue of $42.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $28.0 Million ; Positive Momentum e...
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...